1-4 of 4
Alma R. Oskarsdottir
Close
Sort by
Journal Articles

Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study

Clinical Trials & Observations
Alma R. Oskarsdottir, Brynja R. Gudmundsdottir, Hulda M. Jensdottir, Bjorn Flygenring, Ragnar Palsson, Pall T. Onundarson
Journal: Blood
Blood (2021) 137 (20): 2745–2755.
https://doi.org/10.1182/blood.2020008698
Published: 2021
Includes: Supplemental data
Journal Articles

Replacing PT-INR Monitoring of Warfarin with Fiix-NR in Clinical Practice Reduces Thromboembolism without Increasing Bleeding Despite Reduced Number of Dose Adjustments

Alma R. Oskarsdottir, MD, Brynja R. Gudmundsdottir, MS, Pall T. Onundarson, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1239.
https://doi.org/10.1182/blood-2018-99-116731
Published: 2018
Journal Articles

Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial

Alma R. Oskarsdottir, BS, Brynja R. Gudmundsdottir, MS, Olafur S. Indridason, MD MPH, Hulda M. Jensdottir, BS, David O. Arnar, MD PhD, Einar S. Bjornsson, MD PhD, Magnus K. Magnusson, MD, Sigrun H. Lund, PhD, Brynjar Vidarsson, MD, Charles W. Francis, MD, Pall T. Onundarson, MD
Journal: Blood
Blood (2015) 126 (23): 1129.
https://doi.org/10.1182/blood.V126.23.1129.1129
Published: 2015
Journal Articles

Gender Differences during Long-Term Warfarin Anticoagulation in Patients with Atrial Fibrillation Monitored with Fiix-Prothrombin Time or Prothrombin Time. the Fiix Trial

Hulda M. Jensdottir, BS, Brynjar Vidarsson, MD, Brynja R. Gudmundsdottir, MS, Alma R. Oskarsdottir, BS, Olafur S. Indridason, MD MPH, David O. Arnar, MD PhD, Einar S. Bjornsson, MD PhD, Magnus K. Magnusson, MD, Sigrun H. Lund, PhD, Charles W. Francis, MD, Pall T. Onundarson, MD
Journal: Blood
Blood (2015) 126 (23): 1134.
https://doi.org/10.1182/blood.V126.23.1134.1134
Published: 2015